Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb Company (BMY)
:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.96 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)14.98M
Market Cap
$90.66B
Enterprise Value$131.71B
Total Cash (Recent Filing)$13.60B
Total Debt (Recent Filing)$50.93B
Price to Earnings (P/E)18.0
Beta0.25
Next Earnings
Oct 30, 2025EPS Estimate
1.62Last Dividend Ex-Date
Oct 03, 2025Dividend Yield5.64%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,035,435,800
10 Day Avg. Volume21,811,321
30 Day Avg. Volume14,975,893
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda8.73
Forecast
1Y Price Target
$50.93Price Target Upside14.35% Upside
Rating ConsensusHold
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessIberdomide combined with Darzalex plus dexamethasone achieved a statistically significant improvement on the primary endpoint of minimal residual disease negativity rates, versus the control arm.
Financial PerformanceThe I/O and hematology businesses are producing stable cash flows and new launch products are continuing to ramp.
Bears Say
Revenue ExpectationsCobenfy scripts are expected to miss Visible Alpha consensus estimates for 3Q25 revenue.
TRx TrendsCobenfy TRx decreased -12.3% WoW to 1,933 TRx, likely due to the shorter holiday week.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $42.96 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $90.66B.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Oct 30, 2025 which is in 19 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Aug 01, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.091 by $0.369.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Undervalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 5.64%. See more information on Bristol-Myers Squibb Company dividends here
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 1.62.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $1.46 in its last earnings report, beating expectations of $1.091. Following the earnings report the stock price went up 2.13%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$50.93 (14.35% Upside)
$50.93 (14.35% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 350.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.17%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb (BMY) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. The company operates in various therapeutic areas, including oncology, immunology, cardiovascular, and fibrosis, with a strong portfolio of pharmaceuticals and biologics. Core products include well-known drugs such as Opdivo, Eliquis, and Revlimid. BMY is committed to advancing science through research and collaborations to address unmet medical needs.
BMY Company Deck
BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in the growth portfolio and successful strategic initiatives, with increased revenue and earnings guidance. Despite challenges in the legacy portfolio and some study outcomes not meeting expectations, the company is well-positioned for long-term growth with a robust pipeline and strategic partnerships.View all BMY earnings summariesBMY Revenue Breakdown
53.29% Legacy Portfolio
46.71% Growth Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$50.93
▲(14.35% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
22.95% Mutual Funds
15.97% Other Institutional Investors
35.26% Public Companies and Individual Investors